UP!

XLRN $178.75

XLRN target price
178.75
0
0
Acceleron Pharma, Inc.
Traded as NASDAQ: XLRN
Industry Biotechnology
Founded 2003 (2003)
Headquarters Cambridge, Massachusetts, United States
Key people
  • Habib Dable (CEO)
  • Steve Ertel (COO)
  • Matt Sherman (CMO)
  • Kevin McLaughlin (CFO)
  • Francois Nader (Chairman)
Website acceleronpharma.com
Footnotes / references
Key People

Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Boston, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Acceleron has four drugs in clinical trials, and one in preclinical development.

The company was formed in June 2003 in Cambridge, Massachusetts as a Delaware corporation; the original name was Phoenix Pharma.

The founders were scientists Jasbir Seehra, Tom Maniatis, Mark Ptashne, Wylie Vale, and scientific advisor Joan Massague, and business people and investors John Knopf and Christoph Westphal of Polaris Venture Partners, who served as founding CEO. The company was founded to discover and develop drugs based on the scientific discoveries of the scientific founders in the field of growth factors and transforming growth factors in the fields of metabolic disorders like obesity, diabetes, osteoporosis, and muscle-wasting conditions.

The company began with a seed round from Polaris of $250,000 and then had a Series A venture capital investment of $25 million that it used to open its first laboratory in December 2003.

Glenn Batchelder was appointed president and CEO in June 2004.

It started its first clinical trial in June 2006; the product was ACE-011 (which eventually was named "sotatercept"), a protein therapeutic that was an activin type 2 receptor antagonist intended to treat bone loss. ACE-011 was a chimeric protein, created by fusing the binding portion of the activin type 2 receptor to part of an antibody; the resulting protein binds to activin and prevents it from acting.

Knopf took over as CEO in 2007. He became known for showing pictures of a Belgian Blue cow to potential inventors, as a way of illustrating the company's products' potential to develop muscle.

In 2008 Acceleron and Celgene started a partnership to jointly develop and market ACE-011 in which Celgene paid Acceleron $50 million up front and bought $5 million of Acceleron stock, and agreed to buy $7 million more in stock if Acceleron went public, and agreed to pay up to $510 million in milestones. In a separate deal done at the same time, Celgene acquired an option to license three products in Acceleron's pipeline directed to cancer and cancer-related bone loss.

In 2011 Acceleron extended its their partnership with Celgene to include ACE-536, a development candidate for anemia; Celgene paid $25 million upfront, with potential downstream payments of $217 million in milestones and royalties over 10%.

The company held its initial public offering in September 2013. At that time, the company had three protein therapeutic candidates being studied in 12 Phase 2 clinical trials, including sotatercept and luspatercept (ACE-536) which promoted red blood cell production and were being tested as potential treatments for anemia in people with thalassemia and myelodysplastic syndromes (MDS); its other candidate was dalantercept (ACE-041), an angiogenesis inhibitor as a potential cancer drug.

In September 2016 Knopf retired and the company hired Habib Dable as CEO; at that time the company's lead product luspatercept was in Phase III testing for MDS and beta-thalassemia.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2021 2022-02-23 Future report Set alerts
Q3 2021 2021-11-04 0.00 0.00
Q2 2021 2021-08-05 -1.05 -1.05
Q1 2021 2021-05-06 -1.05 -1.05
Q4 2020 2021-02-25 0.00 0.00
Q3 2020 2020-11-05 0.00 0.00
Q2 2020 2020-08-06 -0.34 -0.34
Q1 2020 2020-05-11 -0.95 -0.95
Q4 2019 2020-02-27 -0.44 -0.44
Q3 2019 2019-11-06 -0.86 -0.86

Ratings

2016-07-10 Reiterated Rating Credit Suisse Group AG Buy
2016-06-29 Reiterated Rating Morgan Stanley Overweight
2016-06-13 Boost Price Target Barclays Overweight $40.00 to $42.00
2016-06-13 Reiterated Rating FBR & Co. Buy $63.00
2016-06-13 Boost Price Target Barclays PLC Overweight $40.00 to $42.00
2016-06-13 Reiterated Rating FBR & Co Buy $63.00
2016-06-12 Reiterated Rating Leerink Swann Buy
2016-06-10 Reiterated Rating Piper Jaffray Buy
2016-06-10 Reiterated Rating Piper Jaffray Cos. Buy
2016-04-27 Initiated Coverage Barclays Overweight $40.00
2016-04-17 Reiterated Rating Oppenheimer Buy
2016-04-17 Reiterated Rating Oppenheimer Holdings Inc. Buy
2016-02-29 Upgrade Janney Montgomery Scott Neutral to Buy $45.00 to $39.00
2016-02-27 Reiterated Rating Piper Jaffray Buy
2016-02-27 Reiterated Rating FBR & Co. Buy
2016-02-01 Reiterated Rating Oppenheimer Outperform $58.00
2016-01-20 Initiated Coverage Credit Suisse Outperform $50.00
2016-01-20 Initiated Coverage Credit Suisse Group AG Outperform $50.00
2016-01-16 Initiated Coverage FBR & Co. Buy
2016-01-15 Boost Price Target FBR & Co. Outperform $60.00 to $63.00
2015-12-17 Reiterated Rating Janney Montgomery Scott Neutral
2015-12-07 Reiterated Rating Oppenheimer Buy $58.00
2015-11-19 Initiated Coverage Oppenheimer Outperform to Outperform $58.00
2015-10-06 Reiterated Rating Leerink Swann Outperform
2015-08-13 Initiated Coverage Morgan Stanley Overweight $50.00
2015-06-09 Initiated Coverage Guggenheim Neutral
2015-04-02 Initiated Coverage FBR & Co. Hold $60.00
2015-03-03 Boost Price Target JMP Securities Market Outperform $52.00 to $58.00
2015-03-03 Boost Price Target Citigroup Inc. Buy $50.00 to $52.00
2015-02-02 Reiterated Rating FBR & Co. Outperform $57.00
2015-01-09 Initiated Coverage Janney Montgomery Scott Buy $51.00
2014-08-14 Initiated FBR Capital Outperform $47
2014-08-14 Initiated Coverage Leerink Swann Outperform $57.00
2014-08-13 Initiated Coverage FBR & Co. Outperform $47.00
2014-01-29 Boost Price Target Piper Jaffray Overweight $35.00 to $65.00
2014-01-06 Boost Price Target Citigroup Inc. $50.00
2013-12-12 Reiterated Rating JMP Securities Outperform $32.00 to $36.00
2013-10-14 Initiated Coverage JMP Securities Outperform $32.00
2013-10-14 Initiated Coverage Leerink Swann Outperform
2013-10-14 Initiated Coverage Citigroup Inc. Buy
2013-10-14 Initiated Coverage Piper Jaffray Overweight $32.00
2016-07-10 Reiterated Rating Credit Suisse Group AG Buy
2016-06-29 Reiterated Rating Morgan Stanley Overweight
2016-06-13 Boost Price Target Barclays Overweight $40.00 to $42.00
2016-06-13 Reiterated Rating FBR & Co. Buy $63.00
2016-06-13 Boost Price Target Barclays PLC Overweight $40.00 to $42.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks